Tema Etfs LLC Has $921,000 Holdings in IDEAYA Biosciences, Inc. $IDYA

Key Points

• Tema Etfs LLC has increased its stake in IDEAYA Biosciences by 249.8%, owning a total of 56,204 shares valued at approximately $921,000 as of the latest SEC filing.
• Several institutional investors have also significantly increased their holdings in IDEAYA, with ownership among institutional investors and hedge funds reaching 98.29% of total shares.
• Analysts have mixed ratings on IDEAYA, with a consensus price target of $47.10 and several firms recently issuing "buy" or "overweight" ratings for the stock.

Tema Etfs LLC grew its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 249.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 56,204 shares of the company's stock after purchasing an additional 40,138 shares during the period. Tema Etfs LLC owned approximately 0.06% of IDEAYA Biosciences worth $921,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Janus Henderson Group PLC grew its stake in shares of IDEAYA Biosciences by 13.5% in the 4th quarter. Janus Henderson Group PLC now owns 5,857,639 shares of the company's stock valued at $150,606,000 after purchasing an additional 695,263 shares during the period. Vanguard Group Inc. grew its position in IDEAYA Biosciences by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 5,092,619 shares of the company's stock worth $83,417,000 after acquiring an additional 14,535 shares during the last quarter. Deerfield Management Company L.P. Series C grew its position in IDEAYA Biosciences by 5.5% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 2,736,000 shares of the company's stock worth $70,315,000 after acquiring an additional 142,000 shares during the last quarter. Fiera Capital Corp grew its position in IDEAYA Biosciences by 2.1% during the 1st quarter. Fiera Capital Corp now owns 1,209,865 shares of the company's stock worth $19,818,000 after acquiring an additional 25,398 shares during the last quarter. Finally, Bank of America Corp DE grew its position in IDEAYA Biosciences by 5.9% during the 4th quarter. Bank of America Corp DE now owns 747,934 shares of the company's stock worth $19,222,000 after acquiring an additional 41,390 shares during the last quarter. 98.29% of the stock is currently owned by institutional investors.

IDEAYA Biosciences Price Performance

Shares of IDYA stock traded down $0.38 during trading hours on Monday, reaching $24.55. The company had a trading volume of 632,810 shares, compared to its average volume of 865,656. The company has a 50 day moving average of $23.26 and a 200 day moving average of $20.46. The firm has a market cap of $2.15 billion, a price-to-earnings ratio of -6.48 and a beta of 0.12. IDEAYA Biosciences, Inc. has a 1-year low of $13.45 and a 1-year high of $40.25.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.03). The firm had revenue of $6.00 million during the quarter, compared to the consensus estimate of $3.48 million. The firm's revenue for the quarter was up NaN% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.68) earnings per share. As a group, sell-side analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

Analyst Ratings Changes

IDYA has been the topic of a number of research analyst reports. TD Cowen initiated coverage on IDEAYA Biosciences in a research report on Tuesday, July 22nd. They set a "buy" rating on the stock. Royal Bank Of Canada upgraded IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and decreased their price target for the stock from $57.00 to $30.00 in a research report on Wednesday, July 9th. Wells Fargo & Company began coverage on IDEAYA Biosciences in a research report on Thursday, June 26th. They set an "overweight" rating and a $44.00 price target on the stock. JPMorgan Chase & Co. upped their price objective on IDEAYA Biosciences from $66.00 to $72.00 and gave the stock an "overweight" rating in a report on Monday, July 28th. Finally, The Goldman Sachs Group raised IDEAYA Biosciences to a "hold" rating and set a $25.00 price objective on the stock in a report on Thursday, July 10th. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $47.10.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.